EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Oseltamivir-induced hepatotoxicity: A retrospective analysis of the FDA adverse event reporting system

Lurong Yu, Qiumeng Xiang, Limei Liu iD

PLOS ONE · 2025

DOI: 10.1371/journal.pone.0314970 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Lurong Yu und 2 weiteren Autor:innen. Beteiligte Einrichtung: College of Traditional Chinese Medicine of Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Oseltamivir, Chemical and Drug Induced Liver Injury, Adverse Drug Reaction Reporting Systems, Antiviral Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chongqing Science and Health Joint Medical Research Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Assessing the potential for oseltamivir-induced liver damage is essential to ensure its safe administration. The aim of this study was to examine the association between hepatotoxicity and oseltamivir use and to describe the features of oseltamivir-induced hepatotoxicity. Data were obtained from the Adverse Event Reporting System of the US Food and Drug Administration (FAERS). Disproportionality and proportionality analyses were performed to evaluate the safety profile of oseltamivir-related hepatotoxicity and the occurrence of hepatotoxicity-related adverse events across sex and age groups. The FAERS recorded 20,340,254 adverse event reports between 2004 and 2023, of which 16,960,996 reports were included in the analysis. We identified 14 types of oseltamivir-related adverse events that were hepatotoxic and showed positive signals. The most frequently reported adverse event was abnormal hepatic function (n = 54), and the most severe adverse event was fulminant hepatitis. Compared with that for male individuals, the reporting odds ratio (ROR) was 0.5 for female individuals; and for male individuals, the ROR, compared with that for female individuals, was 4.19. The median time to hepatotoxic adverse events, excluding mixed liver injury, was < 5 days. Oseltamivir can cause liver toxicity, which is influenced by sex and age. Liver function tests and monitoring for signs of liver disease are crucial when using oseltamivir.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OseltamivirChemical and Drug Induced Liver InjuryAdverse Drug Reaction Reporting SystemsAntiviral AgentsHumansMaleFemaleUnited StatesUnited States Food and Drug AdministrationMiddle AgedAdultRetrospective StudiesAgedAdolescentYoung AdultChildChild, PreschoolInfantAged, 80 and over

Substanzen

OseltamivirAntiviral Agents

Autor:innen und Institutionen

  • College of Traditional Chinese Medicine of Chongqing Medical University, Chongqing, China.
  • Pharmacy Department of Chongqing Youyoubaobei Women and Children's Hospital, Chongqing, China.

ORCID-Profile: Limei Liu

Förderung

  • Chongqing Science and Health Joint Medical Research Program

Zitieren

APA

Yu, L., Xiang, Q., & Liu, L. (2025). Oseltamivir-induced hepatotoxicity: A retrospective analysis of the FDA adverse event reporting system. PLOS ONE. https://doi.org/10.1371/journal.pone.0314970

Vancouver

Yu L, Xiang Q, Liu L. Oseltamivir-induced hepatotoxicity: A retrospective analysis of the FDA adverse event reporting system. PLOS ONE. 2025. doi:10.1371/journal.pone.0314970

BibTeX
@article{Yu2025,
  author = {Yu, Lurong and Xiang, Qiumeng and Liu, Limei},
  title = {Oseltamivir-induced hepatotoxicity: A retrospective analysis of the FDA adverse event reporting system},
  journal = {PLOS ONE},
  year = {2025},
  doi = {10.1371/journal.pone.0314970}
}
Kostenlos starten →